BIO 2015 Dispatches: Acorda CEO Cohen To Bring 'Passion' To BIO Chairmanship
This article was originally published in The Pink Sheet Daily
Executive Summary
Congenial Acorda CEO Ron Cohen is chosen to lead the industry group during the upcoming year as the biotech industry gathers in Philadelphia for BIO's annual conference.
You may also be interested in...
Ampyra Approval: Acorda's Lessons Learned
There are many factors that contributed to Acorda's success in gaining approval for Ampyra (dalfampridine), but looking back at the process, CEO Ron Cohen and Chief Scientific Officer Andy Blight agree that the biggest asset was having a Special Protocol Assessment for the Phase III trials.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.